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In renal transplantation blood cyclosporine levels soon after
surgery act as a major determinant of rejection: Insights from
the MY.S.S. Trial.
Background. Target organs express antigens recognized di-
rectly by antigen-specific T cells, and their recognition is crucial
to precipitate rejection. Then, the earliest T-cell activation is in-
hibited by cyclosporine A (CsA), the lowest would be the risk
of rejection. Here, we aimed to assess this possibility in a large
cohort of de novo kidney transplant recipients participating in
an ongoing clinical trial, the Mycophenolate Steroid-Sparing
(MY.S.S.) Trial.
Methods. Three-hundred-thirty-four patients entered the
prospective, multicenter MY.S.S. trial. The main aim of the study
was to assess the predictive value of serial evaluation of blood
CsA trough concentration (C0) and 2-hour postdose drug (C2)
levels alone or in combination, and to identify which is the criti-
cal posttransplant measurement to target CsA therapy in order
to minimize the risk of acute rejection. A very large number of
CsA trough (N = 2236) and C2 (N = 2128) measurements dur-
ing the first 6 months postsurgery were available for analysis.
Patients with delayed graft function were excluded.
Results. CsA trough levels measured at day 2 posttrans-
plant were the strongest predictor of acute graft rejection over
6-month follow-up. Levels within 300 to 440 ng/mL were associ-
ated with the lowest risk of rejection, while for levels lower than
300 ng/mL, the risk of acute rejection was more than doubled.
Higher levels failed to provide any further protection from graft
rejection. CsA trough values predicted allograft rejection with
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an accuracy of 74%, while C2 levels considered alone had no
predictive values at all.
Conclusion. Findings that among serial daily measurements
posttransplant those taken as early as at day 2 have by far
the highest capacity to predict rejection episodes, underline the
need of targeting CsA therapy very early posttransplant with the
goal to modulate early enough T-cell activation at the interface
between the recipient’s blood and the graft where alloimmune
response actually initiates.
Acute rejection remains a significant problem in or-
gan transplantation and may negatively impact long-term
graft survival [1]. Recent studies have enhanced our un-
derstanding of the alloimmune response and provided
evidence of a complex interplay of T-cell subsets, antigen-
presenting cells (APC) and cytokines in the early events
eventually leading to acute graft rejection [2]. While some
authorities were used to believe that recipient T cells en-
gage donor antigens on professional APC in secondary
lymphoid organs, such as lymph nodes [3, 4], recent ev-
idence suggests a critical role of direct interaction of
T cells-endothelial cells within the graft in mediating
acute rejection [5]. Clinically, acute rejection manifests
several days posttransplant, but T cells, according to this
possibility, may meet transplant antigens and prolifer-
ate just immediately after surgery. Such alloimmune re-
sponse eventually drives graft destruction. Cyclosporine
(CsA) and other immunosuppressants overcome host im-
mune reaction to allograft by inhibiting or modulating
T-lymphocyte proliferation, an event that stems from the
inhibition of intracellular key cytokine production [6].
If target organs express antigens that are recognized by
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inspecting antigen-specific T cells directly, and their
recognition is crucial to precipitate rejection, then the
earliest T-cell activation is inhibited by CsA the lowest
would be the risk of rejection.
Here, we addressed this possibility in a large cohort of
de novo kidney transplant recipients participating to an
ongoing clinical trial, the Mycophenolate Steroid-Sparing
(MY.S.S.) Trial. This is a prospective, randomized, multi-
center, European study aimed at comparing the steroid-
sparing potential of a mycophenolate mofetil (MMF)- or
azathioprine-based regimen, with patients entering the
steroid tapering/withdrawal phase at 6 months posttrans-
plantation.
The results of these analyses form the basis of the
present paper.
METHODS
Patients and immunosuppressive regimens
Recipients (≥17 years old) of a first kidney transplant
from cadaver donors referred to nine Italian Renal Trans-
plant Centers of the MY.S.S. study organization since
October 1997 to May 2001, providing written informed
consent and followed prospectively for a minimum of
6 months, were included in the present study. The study
was approved by the Ethics Committees of all partici-
pating centers. All patients were on triple immunosup-
pressive therapy, including CsA Neoral (Novartis, Basel,
Switzerland), corticosteroids, and a nucleoside synthesis
inhibitor azathioprine (Glaxo Wellcome, Verona, Italy)
or MMF (Roche, Milan, Italy). Allocation to azathio-
prine or MMF was in a randomized fashion according
to the design of the MY.S.S. Trial, an ongoing clinical trial
aimed at investigating the steroid sparing potential of a
MMF-based immunosuppressive regimen. Patient allo-
cation to one of the two treatment groups was performed
on the day of transplant. The random allocation sequence
was generated by an independent treatment assignment
secretariat, following a simple randomization list. Imple-
mentation of the random allocation sequence was done
by a central telephone, maintaining the sequence con-
cealed until interventions were assigned.
During the study CsA dosing was targeted to blood
CsA trough ranges of 250 to 440 ng/mL, 200 to 300 ng/mL,
and 150 to 250 ng/mL to be achieved and maintained from
day 0 to 7, day 8 to 30, and months 2 to 6 posttransplant,
respectively [7]. The first dose of CsA was given at the end
of the kidney transplant, and was on average 4 mg/kg/day
for centers who started with intravenous infusion and
8 mg/kg/day for those who began with the oral administra-
tion. After intraoperative infusion of 500 mg methypred-
nisolone, steroid dosing was then progressively tapered
from 200 mg/day intravenously to 50 mg/day orally be-
tween day 1 and 6 posttransplant. Thereafter, a further
dose reduction up to 16 mg/day on day 12 postsurgery
was scheduled. This steroid dosage remained unchanged
until the end of month 2, when the drug was tapered
to 12 mg/day for further 2 months. From the beginning
of month 5 posttransplant patients received the main-
tenance 8 mg/day dose. According to body weight, aza-
thioprine was given at the dose of 100 to 150 mg once
daily, whereas MMF was administered at the fixed dose of
2 g/day, in two separate administrations [7]. The primary
outcome variable was the incidence of acute rejection
episodes over the first 6 months after transplantation.
The present analysis excluded patients who developed
delayed graft function, since in such instance most cen-
ters temporarily discontinued CsA until renal function
recovered, and because the difficulty of diagnosing acute
rejection in the presence of delayed graft function.
Aims of the study
The main aim of this study was to assess the predictive
value of serial evaluations of blood CsA trough concen-
trations (C0), and to identify which is the critical post-
transplant evaluation to target CsA therapy in order to
minimize the risk of acute graft rejection in de novo kid-
ney transplant recipients. Second, the study sought to in-
vestigate the predictive value of 2-hour postdose drug
(C2) levels, measured in parallel with CsA trough lev-
els, and to assess the predictivity of this pharmacokinetic
parameter—alone or in combination with C0 to estimate
the full area under the time CsA concentration curve
(AUC) [8–11]—as compared to C0. The final aim was
to identify a target range of the best predictive pharma-
cokinetic parameter that allowed the highest accuracy in
predicting the risk of rejection and the optimal time of
monitoring this parameter and targeting CsA therapy to
this target in order to minimize the probability of acute
allograft rejection.
Procedures
Whole blood samples were collected just before and
at 2 hours after CsA dosing daily for the first 15 days
and thereafter at month 1, 2, 3, 4, 5, and 6 posttrans-
plant. The drug concentrations at the two sampling points
were designated as C0 and C2, respectively. Time zero
whole blood CsA concentration corresponded to blood
sampling at 12 hours after the previous evening drug
dose. Measurements of CsA concentration in the blood
samples were centralized at the Laboratory of Clinical
Pharmacology of the Clinical Research Center of Rare
Diseases “Aldo e Cele Dacco`” of the Mario Negri Insti-
tute for Pharmacological Research and performed using
the high-performance liquid chromatography (HPLC)
[12]. In addition, the AUC0-12h was estimated by using
the two-point (C0 and C2) method according to the equa-
tion proposed by Keown et al [13], AUC = 12.34 ×
[0 hours] + 2.48 × [2 hours] + 441.42.
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After kidney transplantation, the clinical status of
patients was closely monitored. Each visit included a
physician’s assessment of clinical history and physical
examination, as well as a complete blood count and si-
multaneous multiple analysis of 20 chemical constituent
laboratory test panel.
The rejection episode was diagnosed on the basis of
clinical judgment by the following criteria: ≥0.3 mg/dL
increase in serum creatinine concentration over the previ-
ous evaluation in the presence of expected CsA C0 blood
levels, associated with renal ultrasound findings excluding
urinary tract obstruction or other surgical complications.
It was suggested that if clinical and/or laboratory signs
indicated the occurrence of a rejection episode, a renal
biopsy had to be performed, unless this was medically
contraindicated. For the purpose of this analysis, we con-
sidered only the first postsurgery occurrence of an acute
rejection episode as an “event of acute rejection.”
Statistical analysis
The demographic, clinical, and laboratory data at hos-
pitalization and during the follow-up after transplanta-
tion (up to end of the 6th month) were collected according
to the study protocol by dedicated case form, uniformly
coded, validated, and stored in a computer database sys-
tem for further data management and statistical analyses.
The input data were handled and transferred into SAS
data management system with a conversion from mul-
tidimensional datasets to a bidimensional database. A
specific SAS software protocol for data transfer, filtering
and recoding was written and a final, complete follow-
up database of more than 9000 variables created (SAS
software, version 8.0).
According to the design and aim of this study, a spe-
cific descriptive and analytical approach was undertaken.
Data were analyzed by descriptive statistics, frequency
distribution, parametric and nonparametric comparison
tests (Student unpaired t test, Wilcoxon rank-sum test, or
v 2 test, as appropriate), univariate and multivariate logis-
tic regression, and Cox proportional hazard models, and
receiver operating characteristic (ROC) curve. The sta-
tistical significance of the tests was assumed at P = 0.05.
Prior to the analyses, the skewed distribution of CsA C0,
C2 and AUC was log-transformed, using the natural loga-
rithm base. All evaluations were done with SAS software
(version 8.0). Data are mean (SD) or number and percent
frequency, unless otherwise stated.
A range of clinical, laboratory, and demographic vari-
ables such as CsA levels (C0, C2, AUC) as single values
per visit or mean estimates over a number of visits, hu-
man leukocyte antigen (HLA) matching with the donor,
antirejection treatment, time span to acute rejection, age
and gender were selected as factors and used in the multi-
variate analysis. For the regression models, different num-
Table 1. Demographic characteristics of patients in the study
Patients number 334
Male/female number 218/116
Age years 44 (17–71)
Cadaveric transplantation % 100
Delayed graft functiona number 110
Follow-up months 6
aExcluded from the analyses.
ber of patients had measures for all variable included
in the analysis, according to the specific day, outcome
levels, and main predictors and covariates. The analytic
approach consisted first of descriptive analysis of ba-
sic statistical parameters (mean, SD, variation, range).
Thereafter, comparison of groups of patients and analysis
of temporal variations of CsA C0, C2, and AUC, accord-
ing to the outcome status was performed. We then applied
logistic regression analysis by the entry method with ad-
justment for confounding effects; Cox logistic regression
analysis to adjust the significance of predictive models for
time-to-event effects; logistic curve estimation and ROC
analysis to test the predictive performance and determine
potential cut-off values in the range of CsA C0, C2, and
AUC; and Kaplan-Meier analysis to verify the discrimi-
nant validity of the identified cut-off values and ranges,
considering the time-to-event effects with long-rank test
for statistical significance of cumulative probability dif-
ferences [14].
It should be noted that the ROC curves (Analyze-it
for Microsoft Excel, Trial version 1.62) [15] were used to
determine the true positive rate (sensitivity) as the pro-
portion of cases with the event (e.g., acute rejection) that
were classified at lower values of the predictor (e.g., C0)
and the true negative rate (specificity) as the proportion
of those without the event who were classified at higher
values, not only at the usually accepted cut-off level of 0.5,
but also at the whole range of probabilities from 0 to 1.
These numbers were plotted against each other for each
possible cut-off value to produce the whole ROC curve. A
larger area under the curve indicates better performance
of the predictor. In this way, the scrutiny approach to our
database resulted in an acceptable internal validation of
the fitted logistic regression and survival models.
RESULTS
Three-hundred-thirty-four patients (218 males and 116
females) entered the study (Table 1). 46% of transplant
recipients had two HLA matches with the donor, 28%
had three, and 23% had one. Over 6 months postsurgery,
111 (33.23%) patients (75 males and 36 females) had
at least one acute rejection episode, most of the rejec-
tions (93) occurring during the first month posttransplant.
Of these, 48.7% rejection episodes were biopsy proven.
Graft and patient survival at 6 months posttransplant was
Perico et al: CsA levels and acute graft rejection 1087
Table 2. Association between cyclosporine A pharmacokinetic
parameters at day 2 posttransplant and the occurrence of the first
acute rejection over 6-month follow-up
Acute graft rejection
Parameter No Yes P valuea
C0 ng/mL 539 ± 250 335 ± 248 0.0166
C2 ng/mL 823 ± 368 962 ± 360 0.3100
AUC ng/mL.hour 9451 ± 3069 7046 ± 2718 0.0346
AUC is area under concentration time curve.
aP values determined by two-sided t test.Values are mean ± SD.
97% (end point dialysis) and 98%, respectively. Overall,
the mean renal function, as serum creatinine, at the end
of the 6-month follow-up was 1.52 ± 0.60 mg/dL, with
higher values in patients who had one or more rejec-
tion episodes (rejection, 1.73 ± 0.71 mg/dL; no rejection,
1.42 ± 0.52 mg/dL).
Throughout this period these patients compared to
those without acute rejection had significantly lower av-
erage C0 (274 ng/mL vs. 310 ng/mL, P = 0.007), and AUC
(7071 ng/mL.hour vs. 7867 ng/mL.hour, P = 0.009), but
not C2 (1296 ng/mL vs. 1359 ng/mL, P = 0.206) levels.
When single C0 and C2 daily evaluations were consid-
ered, statistically significant differences were found only
for C0 and AUC values, being these significant differences
detectable at day 1 (C0, P = 0.009; AUC, P = 0.0078) and
day 2 (C0, P = 0.0166; AUC, P = 0.0346) posttransplant
for both parameters (Table 2). Corresponding differences
in daily C2 evaluations failed to achieve the statistical sig-
nificance at each time point throughout the whole study
period.
Predictors of first acute rejection
When single daily posttransplant values were consid-
ered, the C0 and AUC (but not C2) measurements at
day 2 postsurgery were significantly associated with the
risk of rejection, being the predictivity of C0 (P = 0.010)
even superior to that of AUC (P = 0.032). Both C0
and AUC retained their independent predictive value
when HLA matching (C0, P = 0.0281; AUC, P = 0.0479)
or azathioprine/MMF antirejection treatment (C0, P =
0.0046; AUC, P = 0.0159) was added as a covariate, and
even after adjusting (by Cox regression analysis) for the
time to event, again with a superior predictive value for
C0 (P = 0.0031) than for AUC (P = 0.0249). Even by
these approaches, C2 levels did not predict posttransplant
rejection.
At logistic regression analysis, the accuracy in pre-
diction of first acute rejection (74.4% vs. 77.4%) of C0
and AUC was comparable with slightly higher sensitivity
(56.3% vs. 50.0%) and less specificity (87.0% vs. 94.7%)
for C0 than for AUC. As expected, the highest C0 val-
ues yielded the lowest relative risk (RR) of acute rejec-
tion (RR range 0.68 to 0.06), the risk decreasing by 20%
for each unit increase of the log-transformed C0 values.
On the same line, the highest AUC values yielded the
lowest relative risk of acute rejection (RR range 0.79 to
0.005), which decreased by 6% for each unit increase of
log-transformed AUC value.
In addition to confirming the predictive power of
the two pharmacokinetic parameters measured at day 2
posttransplant, and the superior predictive value of C0
(P = 0.0068) as compared to AUC (P = 0.0156), the ROC
curve analysis found that the best combination of sensi-
tivity and specificity (above 60%) allowing for the highest
accuracy in predicting the rejection-free probability was
for C0 CsA blood concentrations ranging from 300 to
440 ng/mL (Fig. 1A), and for AUC values ranging be-
tween 7100 to 8456 ng/mL.hour (Fig. 1B). Patients with
day 2 C0 levels within the estimated range had 14.2% in-
cidence of acute rejection throughout the 6-month study
period, significantly lower than in those with C0 values
below (76.9%, P = 0.009), and comparable to those with
values above (26.3%, P = 0.527) the range (Table 3).
Differences in the incidence of acute rejection between
groups within or below C0 range during the whole study
period were entirely driven by differences observed dur-
ing the first 30 days posttransplant (early rejection, P =
0.0223), being the difference in the incidence of late acute
rejection (from month 2 to 6, P = 0.463) virtually negli-
gible (Table 3).
Kaplan-Meier curves over the 6-month follow-up pe-
riod showed that C0 CsA blood concentration at day 2
within the estimated range was associated with signifi-
cantly (P = 0.0138) higher probability of being rejection-
free at any time point posttransplant than C0 levels below
the range (Fig. 2). The difference in cumulative rejection-
free probability between patients with C0 levels within
and above the range was negligible (P = 0.5729) (Fig. 2).
Patients who achieved the C0 target of 300 to 440 ng/mL
at day 2 posttransplant maintained this range on average
as along as up to day 8 postsurgery.
DISCUSSION
The present results showed that in renal transplant pa-
tients CsA trough (C0) level measured at day 2 posttrans-
plant was the strongest predictor of acute graft rejection,
even after adjusting for the time to the event. Data from
various studies make it clear that immunologic factors
such as the extent of HLA matching are relevant as risk
factors for graft rejection [16, 17]. Although we confirmed
HLA matching as an independent predictor of rejection,
adjusting for this covariate had negligible effect on the
predictive values of CsA trough measurement at day
2 posttransplant, further supporting the contribution of
this pharmacokinetic parameter as a major determinant.
Levels within 300 and 440 ng/mL were associated with
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Fig. 1. Receiver operating characteristic (ROC) curves of the first
acute rejection during the first 6 months posttransplant versus the phar-
macokinetic parameters measured at day 2 postsurgery. For a given C0
(A) or area under concentration time curve (AUC) (B), the ordinate
values show the corresponding true-positive rate (fraction of patients
with this C0 or AUC who suffered from acute rejection), and the abscissa
values show the corresponding part of the false-positive rate (fraction
of patients with this C0 or AUC who did not suffer from acute rejec-
tion). The inflection point of the curve (indicated by the thick line) was
chosen as the optimal diagnostic value. The larger area between the
ROC curve and the diagonal line reflects the higher degree with which
the parameter shows a predictive benefit.
the lowest risk of rejection, while for levels lower than
300 the risk of acute rejection was more than doubled.
Higher levels failed to provide any further protection
from graft rejection. CsA trough values predicted allo-
graft rejection with an accuracy (74%) that was close to
that of AUC (77%) levels—taken as an indicator of the
Table 3. Incidence of acute rejection according to whether C0 values
at day 2 posttransplant were below, within, or above the established
range to minimize the event occurrence
Time posttransplant Below Within Above
Number (%)
Day 0–day 30 9 (69.2)a 1 (14.2) 4 (21.0)
Month 2–6 1 (7.6) 0 1 (5.2)
Day 0–month 6 10 (76.9)b 1 (14.2) 5 (26.3)
C0 range, 300–440 ng/ml; aP = 0.022 vs. within; bP = 0.009 vs. within.
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Fig. 2. Rejection-free probability over the first 6 month post-transplant
in patients with day 2 post-transplant C0 levels below, within or above
the range of 300 to 440 ng/mL. Levels below 300 ng/mL were associated
with a significant lower rejection-free probability as compared to levels
within the target range. The cumulative rejection-free probability did
not further increase for levels above 440 ng/mL.
overall, daily patients exposure to the drug [18]—while
C2 levels considered alone had no predictive value at all.
These findings confirm and extend previous evidence that
CsA trough values between 330 and 430 ng/mL in the first
9 days postrenal transplant were associated with the low-
est incidence of acute rejection and did not expose the pa-
tients to an unnecessary toxicity [19]. Finding that among
serial daily measurements posttransplant, those taken as
early as at day 2 had by far the highest capacity to predict
rejection episodes, serves to emphasize the importance
of targeting CsA drug dosing at achieving trough values
in ideal ranges soon after surgery. On the other hand,
failure to detect any predictive value for C2 evaluations
challenges the current view that C2 monitoring is the best
and unique surrogate marker to limit the risk of acute
rejection, at least in kidney transplantation, even early
postsurgery.
The importance of our observation rests on the fact that
the predictivity was based on daily CsA monitoring in the
first 16 days posttransplant and thereafter at monthly in-
tervals. Moreover, the present study is the largest so far
to explore the predictivity of CsA monitoring (including
previous studies taken to suggest the predictive value of
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C2) toward the risk of acute rejection [11, 20, 21]. Here,
we used a very large number of CsA trough (N = 2236)
and C2 (N = 2128) measurements as compared to few
tens or hundreds of measurements available for anal-
ysis in previous studies. Among these, the largest one
was the basiliximab versus antithymocyte globulin multi-
center trial for prevention of acute renal allograft, which
included only 302 C2 measurements [22]. Moreover, re-
sults of most of these studies were based on retrospective
and merely descriptive analyses [23–25], and, in some
cases, were even confounded by combined treatments
with other drugs in addition to steroids and antiprolifer-
ative agents, such as interleukin-2 (IL-2) receptor antag-
onists (namely basiliximab) or antithymocyte globulins
[22].
Most of the predictive value of CsA trough measure-
ments in the present study related to the strong associa-
tion between trough levels and rejections occurring over
the first 30 days posttransplant. Of note, most of the re-
jection episodes (84% in the present series) occur early
postsurgery. Evidence that regional rather than systemic
immune mechanisms critically influence acute rejection
[5, 26, 27] supports the importance of immunosuppressive
interventions that ultimately inhibit activation of host
T cells where they meet transplant antigens and al-
lorecognition occurs. Conventional wisdom holds that
target organs express antigens that are processed and
presented by professional host hematopoietic APCs to
T-helper cells in peripheral lymphoid organs [3, 4], an
event that requires days for full activation. However, re-
cent work in an elegant transgenic animal model system
[5] raised the possibility that first encounter of T cells
with donor antigen may take place in the graft and not
in the peripheral lymphoid organs. In this setting CD8+
T cells can recognize alloantigen on graft endothelial
cells, resulting in allograft rejection even in the absence
of T-helper cells and specialized host APCs. These ob-
servations have relevant implications on the timing of
best immunosuppression threshold to be achieved for
reducing as much as possible the risk of acute graft re-
jection. It is tempting to speculate that achieving the tar-
get CsA trough level as early as day 2 posttransplant
may allow to reach more rapidly the threshold level of
calcineurin inhibition (the putative target of CsA action
[28, 29]) eventually required to prevent T-lymphocyte ac-
tivation/proliferation triggered by local interaction with
donor antigens on the graft endothelial cells [6]. On the
other hand, the impact of early immunosuppressive ther-
apy on later rejection episodes may be less important
since other factors—such as patient compliance, progres-
sive down-titration of the immunosuppressive therapy,
including the reduction in steroid dosage, intercurrent
CMV infection, or concomitant treatments that may in-
terfere with CsA bioavailability [30–32]—may influence
the immune response in the long-term.
CONCLUSION
In a large cohort of de novo kidney transplant re-
cipients CsA trough levels were the best predictors of
acute rejection over 6 months of follow-up. Day 2 post-
transplant CsA blood concentrations identified the ear-
liest time point postsurgery in which drug trough levels
were associated with the lowest risk of graft rejection,
being the levels between 300 and 440 ng/mL the highest
predictors for rejection-free probability. These findings
underline the need of targeting CsA therapy very early
posttransplant with the goal to modulate early enough
T-cell activation at the interface between the recipient’s
blood and the graft where alloimmune response actually
initiates. Results in renal transplantation presented here
may provide a previously unstudied therapeutic mode
for preventing transplant rejection in organs other than
kidney.
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APPENDIX
Participating centers and number of patients enrolled
in the MY.S.S. Trial
G. Locatelli, E. Gotti, P. Ruggenenti, N. Perico, G. Rota, G. Remuzzi
(Azienda Ospedaliera, Ospedali Riuniti, Bergamo—Istituto di Ricerche
Farmacologiche Mario Negri; N = 89); D. Donati, L. Gastaldi (Os-
pedale Regionale di Circolo e Fondazione Macchi, Varese; N = 47); R.
Piperno, E. Bertoni, M. Salvadori (Azienda Ospedaliera Careggi Monna
Tessa, Firenze; N = 44); S. Sandrini, G. Setti, R. Maiorca (Azienda Os-
pedaliera Spedali Civili, Brescia; N = 42); M. Beatini, O. Manolitsi,
U. Valente, G. Cannella (Azienda Ospedaliera San Martino, Genova;
N = 29); G. Segoloni, M. Messina, F. Capurro, M. Rocchietti, S.
Santi, G. Piccoli (Azienda Ospedaliera S. G. Battista, Torino; N =
27); G. Mourad (Hospital Lapeyronie—Center Hospitalier Universi-
taire Montpellier; N = 19); S. Federico (Universita` Federico II, Napoli;
N = 12); P. Rigotti, N. Baldan, L. Liberati, L. Rigoni, E. Ancona
(Ospedale Giustinianeo, Padova; N = 12); S. Calabrese, V. Sparacino
(Ospedale Civico, Palermo; N = 10); and M. E. De Broe, J. L. Bosmans
(University of Antwerp, Antwerp; N = 5).
Laboratory measurements
F. Gaspari, D. Cattaneo, R. Caruso, S. Baldelli, S. Ferrari, N. Stucchi,
S. Zenoni (Mario Negri Institute for Pharmacological Research).
Study monitoring
G. Gherardi, M. Lesti, M. Turturro, R. D’Adda, R. Ghislandi (Mario
Negri Institute for Pharmacological Research).
Statistical analysis
A. Perna, B. D. Dimitrov, M. Ganeva (Mario Negri Institute for Phar-
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